dc.contributor | Departament de Salut |
dc.contributor.author | Sanvisens, Arantza |
dc.contributor.author | Rivas, Inmaculada |
dc.contributor.author | Faure, Eva |
dc.contributor.author | Espinach Garcia, Nestor |
dc.contributor.author | Hernandez-Rubio, Anna |
dc.contributor.author | Majó-Roca, Xavier |
dc.contributor.author | Colom-Farran, Joan |
dc.contributor.author | Muga, Robert |
dc.date.accessioned | 2022-02-07T12:12:03Z |
dc.date.available | 2022-02-07T12:12:03Z |
dc.date.issued | 2020-10-14 |
dc.identifier.citation | Sanvisens A, Rivas I, Faure E, Espinach N, Hernandez-Rubio, A, Majó X, et al. Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study. World J Gastroenterol. 2020 Oct 14;26(38):5874-5883. |
dc.identifier.issn | 1007-9327 |
dc.identifier.uri | https://hdl.handle.net/11351/6983 |
dc.description | Direct-acting antiviral agents; Opioid Treatment Program; Opioid agonist therapy; Hepatitis C virus infection; Human immunodeficiency virus infection; Drug use |
dc.description.abstract | Background: Direct-acting antivirals (DAAs) are recommended for the treatment of hepatitis C virus (HCV) infection in patients treated with methadone or buprenorphine.
Aim: To assess HCV treatment rates in an Opioid Treatment Program (OTP).
Methods: This longitudinal study included 501 patients (81.4% men, median age: 45 years; interquartile range: 39-50 years) enrolled in an OTP between October 2015 and September 2017. Patients were followed until September 2019. Data on socio-demographics, substance use, HCV infection, human immunodeficiency virus (HIV) infection and laboratory parameters were collected at entry. We analyzed medical records to evaluate HCV treatment. Kaplan-Meier methods and Cox regression models were used to analyze the DAA treatment uptake and to identify treatment predictors.
Results: Prevalence of HCV and HIV infection was 70% and 34%, respectively. Among anti-HCV-positive (n = 336) patients, 47.2%, 41.3%, and 31.9% used alcohol, cannabis, and cocaine, respectively. HCV-RNA tests were positive in 233 (69.3%) patients. Twentyeight patients (8.3%) cleared the infection, and 59/308 (19.1%) had received interferon-based treatment regimens before 2015. Among 249 patients eligible, 111 (44.6%) received DAAs. Treatment rates significantly increased over time from 7.8/100 person-years (p-y) (95%CI: 5.0-12.3) in 2015 to 18.9/100 p-y (95%CI: 11.7-30.3) in 2019. In a multivariate analysis, patients with HIV co-infection were twice as likely to receive DAAs (HR = 1.94, 95%CI: 1.21-3.12) than patients with HCV mono-infection. Current drug use was an independent risk factor for not receiving treatment against infection (HR = 0.48, 95%CI: 0.29-0.80).
Conclusion: HCV treatment is evolving in patients with HCV-HIV co-infection. Ongoing drug use while in an OTP might negatively impact the readiness to treat infection. |
dc.language.iso | eng |
dc.publisher | Baishideng Publishing Group |
dc.relation.ispartofseries | World journal of gastroenterology;26(38) |
dc.rights | Attribution-NonCommercial 4.0 International |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ |
dc.source | Scientia |
dc.subject | Infeccions per VIH - Tractament |
dc.subject | Virus de l'hepatitis C - Tractament |
dc.subject | Opiacis - Ús terapèutic |
dc.subject.mesh | HIV Infections |
dc.subject.mesh | Opiate Substitution Treatment |
dc.subject.mesh | Hepatitis C |
dc.title | Monitoring hepatitis C virus treatment rates in an Opioid Treatment Program: A longitudinal study |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.3748/wjg.v26.i38.5874 |
dc.subject.decs | infecciones por VIH |
dc.subject.decs | tratamiento de sustitución de opiaceos |
dc.subject.decs | hepatitis C |
dc.relation.publishversion | http://dx.doi.org/10.3748/wjg.v26.i38.5874 |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.authoraffiliation | [Sanvisens A] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [Rivas I, Faure E, Espinach N] Mental Health and Addiction Service, Badalona Serveis Assistencials-BSA, Badalona, Spain. [Hernandez-Rubio A, Muga R] Department of Internal Medicine, Hospital Universitari Germans Trias i Pujol, Universitat Autònoma de Barcelona, Badalona, Spain. [Majó X, Colom J] Programa de Prevenció, Control i Atenció al VIH, les MTS i les Hepatitis Víriques, Agència de Salut Pública de Catalunya (ASPCAT), Departament de Salut, Generalitat de Catalunya, Barcelona, Spain |
dc.identifier.pmid | 33132641 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |